combination therapies mouse antibody against pd l1 (Bio X Cell)

Bio X Cell is a verified supplier

Bio X Cell manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bio X Cell combination therapies mouse antibody against pd l1

In vivo efficacy of the <t>PD-L1</t> antibody in combination to different therapeutic drugs including gemcitabine solution, Abraxane™, paclitaxel in solution, DHA-SBT-1214 in solution and NE-DHA-SBT-1214 against Panc02 induced syngeneic mice tumors. (A)– Graph summarizing all treatment modalities. The values are means ± SD (n=3). Significant differences are indicated as follows: *p < 0.05, and **p< 0.01. (B)– Tumor images taken at the time of harvest from different treatment modalities. (3b-A)– Tumors from mice treated with vehicle; (3b-B)– Three tumors each from PD-L1 (200μg) treated mice; (3b-C, D)–Tumors from Abraxane™ plus IgG or PD-L1 (200μg) treated mice respectively; (3b-E)– Tumors from NE-DHA-SBT-1214 (10mg/kg) plus IgG (200μg) treated mice; (3b-F, G)– Tumors from gemcitabine plus IgG or PD-L1 (200μg) treated mice respectively; (3b-H)– Tumors from NE-DHA-SBT-1214 (10mg/kg) plus PD-L1 (200μg) treated mice; (3b-I, J)– Tumors from NE-DHA-SBT-1214 (25mg/kg) plus IgG or PD-L1 (200μg) treated mice respectively. (C)– Graph for all the tumors from (3B) to show their progression over time.

Combination Therapies Mouse Antibody Against Pd L1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 412 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/single-cell+spatial+transcriptomics+data/InVivoPlus+anti-mouse+PD-L1/pmc06825580-111-4-19
Average 96 stars, based on 412 article reviews

combination therapies mouse antibody against pd l1 - by Bioz Stars, 2026-09

96/100 stars

Images

1) Product Images from "DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Anti-Tumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model"

Article Title: DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Anti-Tumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model

Journal: Molecular cancer therapeutics

doi: 10.1158/1535-7163.MCT-18-1046

In vivo efficacy of the PD-L1 antibody in combination to different therapeutic drugs including gemcitabine solution, Abraxane™, paclitaxel in solution, DHA-SBT-1214 in solution and NE-DHA-SBT-1214 against Panc02 induced syngeneic mice tumors. (A)– Graph summarizing all treatment modalities. The values are means ± SD (n=3). Significant differences are indicated as follows: *p < 0.05, and **p< 0.01. (B)– Tumor images taken at the time of harvest from different treatment modalities. (3b-A)– Tumors from mice treated with vehicle; (3b-B)– Three tumors each from PD-L1 (200μg) treated mice; (3b-C, D)–Tumors from Abraxane™ plus IgG or PD-L1 (200μg) treated mice respectively; (3b-E)– Tumors from NE-DHA-SBT-1214 (10mg/kg) plus IgG (200μg) treated mice; (3b-F, G)– Tumors from gemcitabine plus IgG or PD-L1 (200μg) treated mice respectively; (3b-H)– Tumors from NE-DHA-SBT-1214 (10mg/kg) plus PD-L1 (200μg) treated mice; (3b-I, J)– Tumors from NE-DHA-SBT-1214 (25mg/kg) plus IgG or PD-L1 (200μg) treated mice respectively. (C)– Graph for all the tumors from (3B) to show their progression over time.

Figure Legend Snippet: In vivo efficacy of the PD-L1 antibody in combination to different therapeutic drugs including gemcitabine solution, Abraxane™, paclitaxel in solution, DHA-SBT-1214 in solution and NE-DHA-SBT-1214 against Panc02 induced syngeneic mice tumors. (A)– Graph summarizing all treatment modalities. The values are means ± SD (n=3). Significant differences are indicated as follows: *p < 0.05, and **p< 0.01. (B)– Tumor images taken at the time of harvest from different treatment modalities. (3b-A)– Tumors from mice treated with vehicle; (3b-B)– Three tumors each from PD-L1 (200μg) treated mice; (3b-C, D)–Tumors from Abraxane™ plus IgG or PD-L1 (200μg) treated mice respectively; (3b-E)– Tumors from NE-DHA-SBT-1214 (10mg/kg) plus IgG (200μg) treated mice; (3b-F, G)– Tumors from gemcitabine plus IgG or PD-L1 (200μg) treated mice respectively; (3b-H)– Tumors from NE-DHA-SBT-1214 (10mg/kg) plus PD-L1 (200μg) treated mice; (3b-I, J)– Tumors from NE-DHA-SBT-1214 (25mg/kg) plus IgG or PD-L1 (200μg) treated mice respectively. (C)– Graph for all the tumors from (3B) to show their progression over time.

Techniques Used: In Vivo

In vivo PD-L1 surface protein expression in response to different therapeutic modalities. (A)– mRNA expression of PD-L1 from different mouse tumor treatment groups analyzed using RT-PCR. Relative gene expression for RT-PCR data was calculated relative to murine β-actin. (B)– Tumor tissue lysate from different treated groups was prepared and protein level of different proteins was analyzed using western blotting. (C)– The bands corresponding to PD-L1 were quantified using Image J software and was normalized relative to band intensities for the corresponding Histone 3 loading controls. The bar represents the mean ± standard deviation of data from at least 3 independent experiments; *p<0.05, **p<0.01.

Figure Legend Snippet: In vivo PD-L1 surface protein expression in response to different therapeutic modalities. (A)– mRNA expression of PD-L1 from different mouse tumor treatment groups analyzed using RT-PCR. Relative gene expression for RT-PCR data was calculated relative to murine β-actin. (B)– Tumor tissue lysate from different treated groups was prepared and protein level of different proteins was analyzed using western blotting. (C)– The bands corresponding to PD-L1 were quantified using Image J software and was normalized relative to band intensities for the corresponding Histone 3 loading controls. The bar represents the mean ± standard deviation of data from at least 3 independent experiments; *p<0.05, **p<0.01.

Techniques Used: In Vivo, Expressing, Reverse Transcription Polymerase Chain Reaction, Gene Expression, Western Blot, Software, Standard Deviation

Histopathological evaluation of the Panc02-induced tumor tissues collected from control and different combination treated mice (hematoxylin & eosin staining). Significant reduction in tumor stroma observed with combination of NE-DHA-SBT-1214 and anti-PD-L1 treated groups. The images were taken at 63x magnification.

Figure Legend Snippet: Histopathological evaluation of the Panc02-induced tumor tissues collected from control and different combination treated mice (hematoxylin & eosin staining). Significant reduction in tumor stroma observed with combination of NE-DHA-SBT-1214 and anti-PD-L1 treated groups. The images were taken at 63x magnification.

Techniques Used: Control, Staining

other:

Article Title: Biomimetic vesicles engineered from modified tumour cells act as personalized vaccines for post-surgical cancer immunotherapy
Article Snippet: RP@SMs (5 mg kg −1 ) were administered subcutaneously on days 6, 9, 13 and 20; anti-PD-L1 antibody (BP0101, BioXCell; 100 μg per mouse) was given intravenously on days 8, 11 and 14.

Article Title: Biomimetic vesicles engineered from modified tumour cells act as personalized vaccines for post-surgical cancer immunotherapy.
Article Snippet: RP@SMs (5 mg kg−1) were administered subcutaneously on days 6, 9, 13 and 20; anti-PD-L1 antibody (BP0101, BioXCell; 100 μg per mouse) was given intravenously on days 8, 11 and 14.

Control:

Article Title: Targeting the Notch1-YY1-ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8 + T-Cell-Driven Cancer Cell Pyroptosis.
Article Snippet: Drugs and Treatment: The γ-secretase inhibitor DAPT (N-[N-(3,5difluorophenacetly L-alanyl)]-S-phenylglycinet-butyl ester, GSI-IX) (Selleck, Cat. no. S2215-30 mg-lsx) was diluted in DMSO (4%) (Sigma, Cat. no. D2650-100ML) and corn oil (96%) (Selleck, S6701-100 mL). .. Anti-PDL1 monoclonal antibody (aPD-L1) (BioXCell, Cat. no. BP0101-25MG) or anti-IgG control antibody (aIgG) (DIA-AN, Cat. no. Q6007-10 mg) was diluted in PBS. .. In vivo jet/PEI regent (Polyplus-transfection, Cat. no. 201–50G) was applied as a carrier for delivering YY1- or ICAM1targeting siRNA to liver tissues.

Article Title: Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8 + T‐Cell‐Driven Cancer Cell Pyroptosis
Article Snippet: The γ‐secretase inhibitor DAPT (N‐[N‐(3,5‐difluorophenacetly L‐alanyl)]‐S‐phenylglycinet‐butyl ester, GSI‐IX) (Selleck, Cat. no. S2215‐30 mg‐lsx) was diluted in DMSO (4%) (Sigma, Cat. no. D2650‐100ML) and corn oil (96%) (Selleck, S6701‐100 mL). .. Anti‐PD‐L1 monoclonal antibody (aPD‐L1) (BioXCell, Cat. no. BP0101‐25MG) or anti‐IgG control antibody (aIgG) (DIA‐AN, Cat. no. Q6007‐10 mg) was diluted in PBS. .. In vivo jet/PEI regent (Polyplus‐transfection, Cat. no. 201–50G) was applied as a carrier for delivering YY1‐ or ICAM1‐targeting siRNA to liver tissues.

Data-independent acquisition:

Injection:

Article Title: Uracil-DNA glycosylase deficiency is associated with repressed tumor cell-intrinsic inflammatory signaling and altered sensitivity to exogenous interferons
Article Snippet: .. For the study involving anti-PD-L1 therapy, mice were injected intraperitoneally with 100 μg anti-PD-L1 antibody (clone 10F.9G2, BioXCell inVivoPlus) diluted in 100 μl inVivoPure pH 6.5 Dilution Buffer (BioXCell), every 3 days for 6 doses, starting on day 2 after tumor cell injection on day 1. ..

Review